Page 1

GENFIT TOWARDS BETTER MEDICINE PRESS RELEASE • GENFIT Reports First - Half 2026 Financial Results and Provides Corporate Update Financial Highlights Cash and cash equivalents totaled € 113.8 million as of June 30 , 2026 ; expected to fund the Company beyond the end of 2028 € 21.1 million in revenues as of June 30 , 2026 , including € 21.0 million in royalties generated under the Ipsen agreement Key Highlights PBC : Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to € 1 billion , underscoring the value creation potential of GENFIT's licensing agreement MASH : Medicare coverage secured in August 2026 in the United States for NASHnextⓇ , the Labcorp- commercialized test based on GENFIT'S NIS ™ technology ; estimated U.S. peak sales of products based on GENFIT'S NIS ™ technology could exceed $ 1.5 billion by 2033 ( IQVIA ) ACLF : Clinical - stage pipeline re - focused on the planned initiation of two Phase 2 clinical trials , of nangibotide and nitazoxanide , before year - end CCA : Continued advancement of GNS561 in combination therapy , including expansion of the Phase 1b study into additional cohorts following encouraging preliminary data ; preparation for a Phase 2 trial expected to commence before year - end Lille ( France ) , Cambridge ( Massachusetts , United States ) ; September 28 , 2026 - GENFIT ( Euronext : GNFT ) , a late - stage biopharmaceutical company dedicated to improving the lives of patients with rare and life - threatening liver diseases , today announced its first half 2026 financial results and provided a corporate update . Pascal Prigent , CEO of GENFIT , commented : " We are pleased with the progress across our businesses and believe we now have a strong platform to build upon . IqirvoⓇ continues to perform above expectations , with royalty revenue more than tripling in the first half of 2026 compared with the same period last year . This momentum could be further supported by the very encouraging ELSPIRE Phase 3 results and is reflected in Ipsen's recent increase in its peak - sales guidance to € 1 billion . At the same time , our MASH diagnostics business is emerging as a potentially significant contributor to future revenues , as the key challenge in this large market is shifting from treatment availability to patient identification and monitoring . Finally , we are starting three distinct Phase 2 studies , with readouts expected next year , each addressing a challenging condition where we believe our programs have the potential to make a meaningful difference . " I. Financial update Cash and cash equivalents As of June 30 , 2026 , the Company's cash and cash equivalents amounted to € 113.8 million compared with € 101.1 million as of December 31 , 2025 . In 2026 , cash consumption was primarily driven by research and development activities across our Acute - on - Chronic Liver Failure ( ACLF ) franchise programs , notably NTZ / G1090N , SRT - 015 , CLM - 022 and VS - 02 HE , as well as our GNS561 program in cholangiocarcinoma ( CCA ) . This cash consumption was offset by two significant cash inflows during the first half of 2026 : ( i ) the second € 30.0 million tranche received under the royalty financing agreement and ( ii ) the receipt of the first commercial milestone payment of € 17.0 million from Ipsen ( USD $ 20.0 million ) , which had already accrued for in 2025 and received in 2026 .. We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028 , enabling the Company to further develop its R & D pipeline and support general corporate purposes . This is based on current assumptions and programs and does not include exceptional events . This estimation assumes ( i ) our expectation to receive significant future commercial milestone revenue pursuant to the Ipsen Agreement and Ipsen meeting its sales - based thresholds and ( ii ) drawing down the third and final , optional installment under the Royalty Financing agreement . Financial highlights GENFIT | 885 Avenue Eugène Avinée , 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1